Health Check: ProMedicus lands $33m deal; Memphasy's RoXsta antioxidant profiling shows potential

Pro Medicus signs $33m deal with University of Kentucky
Memphasys’ RoXsta system advances antioxidant profiling potential
Acrux launches 90-gram Dapsone Gel in US

These are today’s healthcare announcements from the ASX, with major progress being made in medical imaging, treatments, and diagnostics.

ProMedicus (ASX:PME)

PME just landed a $33 million, nine-year deal with the University of Kentucky (UK HealthCare), marking a massive leap into North America’s academic healthcare space.

The deal sees PME’s Visage 7 cloud-based platform replace UK’s old, clunky PACS and vendor-neutral archive systems, providing a next-gen, unified diagnostic imaging solution.

The Visage 7 system includes the Viewer, Open Archive, and Workflow modules, all seamlessly integrating with the UK’s electronic health records.

This upgrade is part of PME’s “CloudPACS strategy”, with PME’s CEO Dr Sam Hupert pointing out that cloud solutions are fast becoming the new standard across North America.

“We’re seeing continued demand across all segments,” said Hupert, as the company aims to build out a pipeline of big-ticket clients in the medical imaging space.

PME’s shares were up 2% at the time of writing.

Memphasys (ASX:MEM)

Memphasys has scored a big win with the publication of a study in Antioxidants journal, showcasing the potential of its RoXsta system to diagnose oxidative stress in human and animal samples.

This breakthrough validates the platform’s ability to profile antioxidants and free radicals, a key factor in conditions like infertility, cardiovascular disease and even cancer.

“This publication is a testament to RoXsta’s transformative capabilities,” said Memphasy’s CEO, David Ali.

The RoXsta system, which offers rapid, precise antioxidant profiling, is already proving its worth in male infertility treatments, disease management and livestock fertility.

The company is now exploring its potential to optimise livestock productivity, and even assess antioxidants in plant-based products and cosmetics.

MEM’s shares jumped 12%.

Acrux (ASX:ACR)

Acrux has teamed up with TruPharma to launch a 90-gram pack of Dapsone 5% Gel in the US, a topical treatment for acne vulgaris.

The acne treatment market is relatively big, with annual sales of Dapsone 5% Gel hitting US$15.8 million as of August 2024.

“While the market for the 90-gram pack size represents only 16% of volume for the product, the offering of both pack sizes will improve the product’s competitive profile,” said Acrux’s CEO, Michael Kotsanis.

“We anticipate a positive impact on market share for the product following this launch.”

This move strengthens Acrux’s foothold in the booming acne market and gives them the upper hand in the cutthroat US scene.

ACR’s shares were up 3%.

Dimerix (ASX:DXB)

Dimerix has hit a milestone with the recruitment of the first paediatric patient for its ACTION3 phase III 3 clinical trial, focusing on children aged 12-17 with FSGS (Focal Segmental Glomerulosclerosis), a leading cause of kidney failure.

The trial, which spans 19 specialist sites across the UK, US, Mexico and Argentina, aims to collect data for potential approval of DMX-200 in paediatric patients, aligning with FDA and EMA expectations.

The trial will use the same dose of DMX-200 as the adult cohort, with recruitment on track for full study enrolment by late Q3 2025.

“The study is entering a very exciting phase as we open the last remaining study sites and work towards full recruitment later this year, as well as the blinded interim analysis anticipated in August 2025, “ said Dimerix’s Chief Medical Officer, Dr David Fuller.

DXB’s shares gained by over 2%.

At Stockhead we tell it like it is. While Dimerix is a Stockhead advertiser, it did not sponsor this article.